Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2069  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal


Year : 2021  |  Volume : 69  |  Issue : 5  |  Page : 1363--1367

Clinical and Molecular Features of First Mexican Friedreich's Ataxia Patients with Compound Heterozygous FXN Mutations

1 Clinical Research Laboratory, Ataxias, Chorea and Other Rare Neurodegenerative Diseases, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez” (INNNMVS), Mexico City, Mexico
2 Department of Genetics, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”; Department of Biological Systems, Metropolitan Autonomous University-Xochimilco, Mexico City, Mexico
3 Department of Genetics, Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, Mexico City, Mexico

Correspondence Address:
Nancy Monroy-Jaramillo
Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Ave. Insurgentes Sur 3877, La Fama, Tlalpan, 14269, Mexico City
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.329555

Rights and Permissions

Background: Friedreich's ataxia (FRDA) is caused by homozygous GAA repeat expansions or compound heterozygous (CH) mutations in FXN gene. Its broad clinical spectrum makes it difficult to identify, thus an accurate diagnosis can only be made by genetic testing. Objective: This study aims to present data on FXN variants observed in patients with sporadic or recessive ataxia, including detailed data of the first CH Mexican patients. Materials and Methods: One hundred and eight patients with recessive or sporadic cerebellar ataxia were referred to our institution between 2009 and 2019 for FXN molecular testing. This was achieved using a combined methodology of triplet repeat-primed PCR (polymerase chain reaction), long PCR, FXN sequencing and multiplex-ligation probe-amplification. Results: Eighteen patients had a homozygous FXN genotype; whereas five were CH patients with a slow progression and phenotypic variability, including a late-onset case with spastic paraparesis, and a Charcot-Marie-Tooth-like case. Conclusions: These first Mexican CH patients pose important implications for genetic counseling and FRDA management.


Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow